<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136274</url>
  </required_header>
  <id_info>
    <org_study_id>EDINV-EENC</org_study_id>
    <nct_id>NCT05136274</nct_id>
  </id_info>
  <brief_title>Evaluation of Ipsilateral Tubal Patency After Conservative Medical or Surgical Treatment.</brief_title>
  <acronym>EENCBE</acronym>
  <official_title>Evaluation of Ipsilateral Tubal Patency After Conservative Medical or Surgical Treatment in Uncomplicated Ectopic Pregnancy, &quot;Hospital General&quot;, Angola 2021-2022</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EDGREM Investimentos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EDGREM Investimentos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ectopic Pregnancy is an entity in which a fertilized ovum is implanted outside its normal&#xD;
      place, is considered a public health problem worldwide and is one of the main causes of&#xD;
      maternal mortality in the first trimester. The availability of high sensitivity methods of&#xD;
      detection of gonadotrophins and the use of high resolution transvaginal ultrasonography have&#xD;
      allowed an earlier diagnosis of the same, enabling less aggressive treatments such as the use&#xD;
      of parenteral MTX, with the intention of avoiding mutilating surgical treatment , preserving&#xD;
      the tube and eventually improving future fertility expectations. The surgical treatment is of&#xD;
      choice, this can be laparoscopically or by laparotomy. In this case, we need to preserve&#xD;
      fertility, the most indicated is linear salpingostomy; In spite of the existence other&#xD;
      techniques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EP constitutes a frequent obstetric emergency in Angola and the province of Benguela is&#xD;
      not exempt from this health problem. Every day we see women with this pathology, to which,&#xD;
      most of them, they undergo a mutilating surgical treatment (salpingectomy) that impedes their&#xD;
      future reproductive capacity. The procreation in the African continent and especially in&#xD;
      Angola, has great social and family implications that can reach the breaking of marriages and&#xD;
      family (broadcast and study of the Public Television of Angola in the program &quot;Na lente&quot; no&#xD;
      year 2018 Taking into account the importance of procreation in the welfare and stability of&#xD;
      the marital relationship.Main Objectiv: To demonstrate the non-inferiority of conservative&#xD;
      treatment with MTX in ipsilateral tubal patency after an uncomplicated ectopic pregnancy&#xD;
      compared with surgical treatment with linear salpingostomy in the Hospital General, Angola&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">August 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled clinical trial comparing ipsilateral tubal patency with the use of two therapeutic methods, groups A; with intramuscular methotrexate administration and B conservative surgery (linear salpingostomy)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Ipsilateral tubal patency</measure>
    <time_frame>A hysterosalpingography will be performed 3 months after the treatment.</time_frame>
    <description>Incidence of Ipsilateral tubal patency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Achieve the gestation and the culmination.</measure>
    <time_frame>Up to two years</time_frame>
    <description>Incidence of Achieve the gestation and the culmination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Ectopic Pregnancy</condition>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>By administering a single intramuscular dose of 50mg / m2 / Sc of Methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will be performed by laparoscopy or laparotomy, using the Linear Salpingostomy technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical treatment</intervention_name>
    <description>The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.</description>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_label>Surgical treatment</arm_group_label>
    <other_name>Surgical treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient presenting with Ectopic Pregnancy, associated with quantitative titers of βHCG ≥&#xD;
        100 mUI / ml, without intrauterine gestational sac.&#xD;
&#xD;
        Patient presenting uncomplicated Ectopic Pregnancy with an adnexal mass diameter ≤4 cm&#xD;
        diagnosed by abdominal and / or transvaginal ultrasonography.&#xD;
&#xD;
        Absence of heartbeat. No toxicity to MTX. Normal laboratory tests (blood count,&#xD;
        coagulogram, liver and kidney function). Hemodynamic stability.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complicated Ectopic Pregnancy.&#xD;
&#xD;
          -  Ectopic pregnancy is out of the tuba on ultrasound&#xD;
&#xD;
          -  Patients with Immunosuppression.&#xD;
&#xD;
          -  Allergy to MTX.&#xD;
&#xD;
          -  Patients with Active Respiratory Disease, Blood Dyspasia, Peptic Ulcer, Renal&#xD;
             Insufficiency and Hepatic Insufficiency.&#xD;
&#xD;
          -  Do not accept to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moreno Araujo</last_name>
    <role>Study Chair</role>
    <affiliation>EDGREN INVESTIMENTOS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARIA DOLORES SABORIDO, MsC</last_name>
    <phone>+244926670289</phone>
    <email>reguera@ywz.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Kedisobua</last_name>
    <phone>+244924951523</phone>
    <email>drkedisobua@yahoo.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maria Dolores Reguera Saborido</name>
      <address>
        <city>Benguela</city>
        <zip>999</zip>
        <country>Angola</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moreno Araujo</last_name>
      <phone>+244926670289</phone>
      <email>reguera@ywz.es</email>
    </contact>
    <investigator>
      <last_name>EDUARDO KEDISOBUA, UNIVERSITY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Angola</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>EDGREM Investimentos</investigator_affiliation>
    <investigator_full_name>Eduardo Kedisobua</investigator_full_name>
    <investigator_title>Medical Surgery</investigator_title>
  </responsible_party>
  <keyword>uncomplicated ectopic pregnancy methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy, Ectopic</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

